X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IRISYS, has been awarded by the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes of the NIH, to develop a new injectable formulation of Drinabant, a selective, high affinity cannabinoid receptor (CB-1) antagonist.
Lead Product(s): Drinabant
Therapeutic Area: Psychiatry/Psychology Product Name: OPNT004
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding January 08, 2021
Details:
TFF Pharmaceuticals contracted with Irisys to manufacture an inhalable lung medication with the potential to treat COVID-19. IRISYS will be responsible for the initial production and testing of TFF’s investigational powder product for inhalation.
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TFF Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 30, 2020
Details:
Preclinical studies at the University of Louisville's (UofL) prestigious Center for Infectious Disease have demonstrated the ability of AS1411 to protect cells from the damaging effects of the novel coronavirus by binding to the nucleolin protein.
Lead Product(s): AS1411
Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Qualigen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 31, 2020
Details:
Irisys is providing contract development and GMP manufacturing services to BioCorRx Pharmaceuticals for a sterile naltrexone sub-cutaneous implant (BICX102) used in treatment of opioid use disorder and the prevention of relapse following opioid detoxification.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioCorRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
